-
公开(公告)号：WO2019140370A1
公开(公告)日：2019-07-18
申请号：PCT/US2019/013468
申请日：2019-01-14
IPC分类号： A61K39/00 , A61K39/395 , A61P31/00 , C07K16/24 , C07K16/28
CPC分类号： A61K39/145 , A61K39/00 , A61K39/3955 , A61K39/42 , A61K47/6913 , A61K47/6929 , A61K2039/505 , A61K2039/55 , A61P31/00 , A61P31/16 , C07K16/248 , C07K16/2827 , C07K16/2866 , C07K2317/76 , A61K2300/00
摘要： The disclosure provides methods for immunizing a subject in need thereof with a prophylactic vaccine against an infectious disease, the method comprising enhancing the subject's immune responsiveness to the vaccine by administering to the subject an agent that transiently inhibits IL-10 production by follicular helper T ("Tfh") cells.
-
公开(公告)号：WO2019089562A1
公开(公告)日：2019-05-09
申请号：PCT/US2018/058172
申请日：2018-10-30
申请人： TROY CORPORATION
CPC分类号： A01N37/02 , A01N31/04 , A01N31/14 , A01N37/06 , A01N37/10 , A01N37/42 , A61K8/34 , A61K8/347 , A61K8/36 , A61K8/365 , A61K8/368 , A61K2800/524 , A61P31/00 , A61P31/04 , A61Q5/02 , A61Q17/005 , A61Q19/00 , A61Q19/007
摘要： The invention is a chemically and physically stable solution of levulinic acid, benzoic acid, and sorbic acids or their salts which is antimicrobially effective against bacteria and fungi. The solution provides improved antibacterial protection for personal care and cosmetic products at lower than expected levulinic acid levels and at desirable use levels. The composition may also include a solvent selected from the group of aromatic alcohols consisting of phenoxyethanol, phenylpropanol, phenylethanol, benzyl alcohol, and mixtures of these alcohols. These solvents extend the range of acidity over which the invention is capable of inhibiting bacterial and fungal growth.
-
公开(公告)号：WO2019069298A2
公开(公告)日：2019-04-11
申请号：PCT/IB2019/050438
申请日：2019-01-18
申请人： ARNOLD, Christian , ARMANI, Armin
发明人： ARNOLD, Christian , ARMANI, Armin
CPC分类号： A61K9/0058 , A61K9/0063 , A61K31/785 , A61K47/02 , A61P31/00 , A61P31/02
摘要： This disclosure describes a chewing gum composition comprising polyhexanide for the treatment and/or prevention of an infectious disease in the oral cavity. The present disclosure also describes a chewing gum composition formulated for the controlled release of polyhexanide and optionally, at least one additional water-soluble antiseptic agent.
-
公开(公告)号：WO2019057110A1
公开(公告)日：2019-03-28
申请号：PCT/CN2018/106677
申请日：2018-09-20
申请人： 沈阳兴齐眼药股份有限公司
IPC分类号： A61K9/10 , A61K9/00 , A61K31/395 , A61K31/165 , A61K47/10 , A61K47/60 , A61P27/06 , A61P35/00 , A61P31/00
CPC分类号： A61K9/00 , A61K9/10 , A61K31/165 , A61K31/196 , A61K31/395 , A61K31/404 , A61K31/436 , A61K31/4745 , A61K31/506 , A61K31/5377 , A61K31/5575 , A61K31/573 , A61K31/58 , A61K45/00 , A61K47/10 , A61K47/14 , A61K47/34 , A61K47/60 , A61P3/10 , A61P7/10 , A61P9/14 , A61P25/00 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/00
摘要： 一种眼用药物组合物，包含固态基质0.06～40重量份、液态基质0.4～55重量份和活性药物成分1重量份；固态基质选自聚乳酸、聚羟基乙酸、聚乳酸-羟基乙酸共聚物和数均分子量800～10000聚乙二醇；液态基质为第一液态基质和/或第二液态基质；第一液态基质选自丁二酸二乙酯、酒石酸二乙酯、戊二酸二甲酯和甘油三醋酸酯；液态基质为第一和二液态基质时，第二液态基质选自甘油、丙二醇和数均分子量70～750聚乙二醇；液态基质为第二液态基质时，第二液态基质为甘油和/或丙二醇或其与数均分子量70～750聚乙二醇的组合。
-
公开(公告)号：WO2019056751A1
公开(公告)日：2019-03-28
申请号：PCT/CN2018/084545
申请日：2018-04-26
申请人： 沈阳兴齐眼药股份有限公司
CPC分类号： A61K9/00 , A61K9/10 , A61K31/165 , A61K31/196 , A61K31/395 , A61K31/404 , A61K31/436 , A61K31/4745 , A61K31/506 , A61K31/5377 , A61K31/5575 , A61K31/573 , A61K31/58 , A61K45/00 , A61K47/10 , A61K47/14 , A61K47/34 , A61K47/60 , A61P3/10 , A61P7/10 , A61P9/14 , A61P25/00 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/00
摘要： 一种眼用缓释药物递送系统，由生物相容性的固态和液态基质以及具有药理活性的药物或其药学上可接受的盐组成。
-
公开(公告)号：WO2019043103A1
公开(公告)日：2019-03-07
申请号：PCT/EP2018/073357
申请日：2018-08-30
发明人： DE MAN, Adrianus Petrus Antonius , UITDEHAAG, Joost Cornelis Marinus , STERRENBURG, Jan Gerard , DE WIT, Joeri Johannes Petrus , VAN CAUTER, Freek , SEEGERS, Nicole Wilhelmina Cornelia , VAN DOORNMALEN, Antonius Maria , BUIJSMAN, Rogier Christian , ZAMAN, Guido Jenny Rudolf
IPC分类号： C07D405/04 , C07D409/04 , C07D409/14 , C07D417/04 , A61K31/4178 , A61P35/00 , A61P25/00 , A61P31/00 , A61P37/00
CPC分类号： C07D409/04 , A61P25/00 , A61P31/00 , A61P35/00 , A61P37/00 , C07D405/04 , C07D409/14 , C07D417/04
摘要： The invention relates to a compound of Formula (I) : Formula (I), or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.
-
公开(公告)号：WO2019034178A1
公开(公告)日：2019-02-21
申请号：PCT/CN2018/101216
申请日：2018-08-18
申请人： 四川百利药业有限责任公司
IPC分类号： C07D487/04 , C07D209/60 , A61K31/395 , A61P31/00 , A61P35/00 , A61P37/00
CPC分类号： A61K31/395 , A61K31/5517 , A61P31/00 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/02 , C07D209/60 , C07D487/04 , C07D519/00
摘要： 本发明公开了一种DNA毒性二聚体化合物，与先前技术公开的苯并二氮杂卓类结合物相比，该细胞毒性化合物显示高得多的体内治疗指数(最大耐受剂量与最低有效剂量的比率)。
-
公开(公告)号：WO2018198084A1
公开(公告)日：2018-11-01
申请号：PCT/IB2018/052936
申请日：2018-04-27
申请人： LUPIN LIMITED
发明人： SINHA, Neelima , KARCHE, Navnath, Popat , KURHADE, Sanjay, Pralhad , JADHAV, Ganesh, Rajaram , HAJARE, Anil, Kashiram , GUPTA, Nishant, Ramniwasji , THUBE, Baban, Rupaji , SHAIKH, Javed, Shafi , PALLE, Venkata, P. , KAMBOJ, Rajender, Kumar
IPC分类号： C07H21/00 , A61K31/7084 , A61P31/00 , A61P35/00
CPC分类号： C07H21/00 , A61K31/7084 , A61P31/00 , A61P35/00
摘要： The present invention relates to cyclic di-nucleotide compounds containing tricyclic heterocycles as nucleobase and having the general Formula (I), (II) and (III) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds containing the present invention.
-
9.发明申请
公开(公告)号：WO2018165501A1
公开(公告)日：2018-09-13
申请号：PCT/US2018/021657
申请日：2018-03-09
申请人： LYCERA CORPORATION
IPC分类号： C07D209/18 , C07D209/08 , C07D235/06 , C07D401/04 , C07D401/12 , C07D405/06 , C07D401/06 , C07D403/06 , C07D401/14 , A61K31/18 , A61K31/10 , A61K31/404 , A61K31/421 , A61K31/4184 , A61P35/00 , A61P31/00 , A61P37/00 , C07D231/56 , C07D235/30 , C07D235/16 , C07D263/56 , C07D413/06 , C07D413/14 , C07D307/79 , C07D307/83 , C07D235/26
CPC分类号： C07D263/56 , A61P31/00 , A61P35/00 , A61P37/00 , C07D209/08 , C07D209/18 , C07D209/30 , C07D231/56 , C07D235/06 , C07D235/16 , C07D235/26 , C07D235/30 , C07D307/79 , C07D307/83 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D405/06 , C07D413/06 , C07D413/14
摘要： The invention provides aryl indolinyl sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORγ activity and/or increasing the amount of IL-17 in a subject, and therapeutic uses of the indolinyl sulfonamide and related compounds, such as treating medical conditions in which activation of immune response is beneficial.
-
公开(公告)号：WO2018133621A1
公开(公告)日：2018-07-26
申请号：PCT/CN2017/117914
申请日：2017-12-22
申请人： 周意
IPC分类号： C07D231/26 , A61K31/4152 , A61P9/10
CPC分类号： A61K31/4152 , A61P1/00 , A61P1/16 , A61P3/10 , A61P9/00 , A61P9/10 , A61P11/00 , A61P13/00 , A61P13/12 , A61P15/00 , A61P17/00 , A61P19/02 , A61P21/00 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/18 , A61P35/00 , A61P37/00 , A61P39/06 , C07D231/26
摘要： 一种依达拉奉衍生物及其用途。该衍生物与依达拉奉相比具有增强的治疗效果和显著降低的细胞毒性。
-
-
-
-
-
-
-
-
-
搜索结果
122 条记录 (耗时 0.017 秒)
